A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.

about

Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile and transcriptional landscape.Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials.

P2860

Q38678106-6BDF216F-6FDB-437D-98E8-281D4EF11D3A Q48097821-A2A49A71-2BA6-4A26-A3A3-8C93C08E8A47

P2860

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.

Item

http://www.wikidata.org/entity/Q40397988

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

A randomized phase 2 study of ...... fractory renal cell carcinoma.

@en

type

Item

label

A randomized phase 2 study of ...... fractory renal cell carcinoma.

@en

prefLabel

A randomized phase 2 study of ...... fractory renal cell carcinoma.

@en

P1476

A randomized phase 2 study of ...... fractory renal cell carcinoma.

@en

P2093

A J Zurita

http://www.w3.org/2001/XMLSchema#string

B Gan

http://www.w3.org/2001/XMLSchema#string

E Hasanov

http://www.w3.org/2001/XMLSchema#string

E Jonasch

http://www.w3.org/2001/XMLSchema#string

K A Do

http://www.w3.org/2001/XMLSchema#string

K R Shaw

http://www.w3.org/2001/XMLSchema#string

L A Doyle

http://www.w3.org/2001/XMLSchema#string

N M Tannir

http://www.w3.org/2001/XMLSchema#string

P F Altamirano

http://www.w3.org/2001/XMLSchema#string

P G Corn

http://www.w3.org/2001/XMLSchema#string

P2860

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway

Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma

Role of VHL gene mutation in human cancer.

Mutant p53: one name, many proteins.

Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.

Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.

Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.

P304

804-808

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDW676

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28049139

http://www.w3.org/2001/XMLSchema#string

P932

5834088

http://www.w3.org/2001/XMLSchema#string

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.

about

P2860

P2860

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932